Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06810167 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06810167 · ClinicalTrials.gov record · last posted 2026-08-21

Assessing Tenapanor as a Treatment of CF-related Constipation.

StatusActive, Not Recruiting
PhasePhase 3
Started2025-06-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Tenapanor is the newest FDA-approved drug for IBS with constipation (IBS-C). This study seeks to understand tenapanor as a treatment for cystic fibrosis-related constipation (CFrC) in CF patients. Participants will ingest one 50 mg tablet of tenapanor, twice daily, for a 4-week treatment period. They will also complete three questionnaires, the PAC-SYM, PAC-QoL, and IBS-SSS, and daily diaries to characterize GI symptom burden and spontaneous bowel movement (SBM) frequency.

Protocol amendment history 1 change detected by DataLookout

2026-08-22
Enrollment closed, study ongoing
Trial Details
NCT Number NCT06810167
Lead Sponsor Massachusetts General Hospital
Collaborators: Ardelyx
Conditions Cystic Fibrosis, Constipation
Enrollment 25 participants
Start Date 2025-06-01
Primary Completion 2026-06-15 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-21